Kyverna Therapeutics

Kyverna Therapeutics is a cell therapy company developing therapies for autoimmune diseases. The company applies T cell engineering and synthetic biology technologies to develop therapies that aim to suppress and eliminate the autoreactive immune cells at the root of inflammatory diseases. Kyverna is collaborating with Gilead Sciences and received Series A investment from Vida Ventures, Westlake Village BioPartners and Gilead Sciences. Kyverna’s collaboration and licensing agreement with Gilead is for the development of engineered T cell therapies for treatment of autoimmune disease using Kyverna’s synthetic Treg platform and the synNotch technology from the Gilead company, Kite Pharma.